U.S. Building Stock News

Apollo Global Management has recently faced pressure after Apollo-managed MidCap Financial Investment Corp. cut its dividend and marked down older assets, while a law firm began investigating potential securities issues tied to past executive discussions about tax arrangements with Jeffrey Epstein. These developments, alongside rising investor focus on credit quality in private-credit funds, have amplified concerns about how resilient Apollo’s broader platform may be to shifts in risk...

Werner Enterprises stock: event context and recent performance snapshot Werner Enterprises (WERN) has drawn investor attention after its latest reported annual results, which showed revenue of US$2.97b and a net loss of US$14.40m, alongside mixed share performance across the past year. See our latest analysis for Werner Enterprises. At a share price of US$35.09, Werner’s recent 90 day share price return of 29.10% and year to date gain of 14.64% point to building momentum. However, the 3 year...

VisionWave Holdings, Inc. recently signed a Memorandum of Understanding with a German aerospace systems provider and an Israeli interceptor drone developer to explore non-explosive interceptor drone solutions for the Bundeswehr and other German government entities, aligned with NATO-related rules-of-engagement and regulatory constraints. This early-stage cooperation highlights growing interest in alternative, non-explosive interception methods that seek to meet strict European defense...

Edwards Lifesciences recently secured U.S. FDA approval for its SAPIEN M3 transcatheter mitral valve replacement system, issued 2026 sales guidance, and saw an FTC injunction block its planned JenaValve acquisition, while an EU antitrust investigation into its policies concluded. These developments collectively reduce legal uncertainty, highlight Edwards’ innovation in structural heart therapies, and align with its goal to broaden global access to cardiovascular treatments by 2030. We’ll now...

Recent share performance and business snapshot J. M. Smucker (SJM) has drawn investor attention after a period of steady gains, with the stock showing positive returns over the past week, month, past 3 months, year to date, and past year. The food and beverage group, which owns brands such as Folgers, Café Bustelo, Dunkin’, Jif, Smucker’s, Meow Mix, Milk-Bone and Hostess, now trades around $115.95 and reports annual revenue of about $8.9b. See our latest analysis for J. M. Smucker. The recent...

PureCycle Technologies (PCT) has drawn fresh investor attention after reporting record fourth quarter production of PureFive recycled polypropylene, advancing its Thailand and Antwerp projects, and outlining a planned CFO transition. See our latest analysis for PureCycle Technologies. Despite record PureFive production and new partnerships, PureCycle’s recent price action has been weak, with a 1 month share price return of a 34% decline and a 1 year total shareholder return of a 38.74%...

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...

Mercury Systems (MRCY) recently reported year over year growth in bookings, revenue, adjusted EBITDA, and backlog, supported by faster customer deliveries and factory automation investments, and outlined new opportunities linked to the defense budget. See our latest analysis for Mercury Systems. At a share price of US$89.03, Mercury Systems has seen a 33.28% 90 day share price return and a very large 100.47% 1 year total shareholder return, suggesting recent momentum has been strong as...

Murphy USA (MUSA) has drawn fresh attention after a cluster of insider stock sales by senior leaders, including its fuels chief and a board director, following recent mixed analyst commentary on the retailer’s latest quarterly update. See our latest analysis for Murphy USA. The recent insider selling comes as Murphy USA’s share price, at US$390.74, shows mixed momentum, with a 30 day share price return of a 7.5% decline, a 3 year total shareholder return of 51.96% and a 5 year total...

What the new shelf registration could mean for Blue Owl Capital Blue Owl Capital (OWL) recently filed a US$615.5 million shelf registration for up to 50,000,000 Class A shares tied to an ESOP related offering, adding a fresh wrinkle to its income focused story. This move arrives alongside management’s commitment to a fixed US$0.92 annual dividend for 2026 and strong demand for its private wealth products, including a 66% year over year increase in dedicated offerings targeting individual...

Bentley Systems (BSY) is back on investors’ radar after its fourth quarter and full year 2025 results beat revenue expectations, and management issued 2026 guidance that came in above prior analyst forecasts. See our latest analysis for Bentley Systems. Even after a strong post earnings bounce, Bentley Systems’ latest share price of US$36.55 still reflects a 12.7% 90 day share price decline and a 16.2% 1 year total shareholder return decline. As a result, the recent 8% 7 day share price gain...

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...

Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness. See our latest analysis for Vera Therapeutics. Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of...

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...

Shift4 Payments (FOUR) is back in focus after a sharp post earnings sell off, weaker forward guidance, and the resignation of Executive Chairman Jared Isaacman. Shares have slid to multi year lows despite ongoing international expansion. See our latest analysis for Shift4 Payments. The weak outlook and leadership change have come on top of a sharp reset in expectations, with a 1 day share price return of 9.0% decline and a 1 year total shareholder return of 55.4% decline, pointing to fading...

Sterling Infrastructure, Inc. has already reported its fourth-quarter and full-year 2025 results, with Q4 sales of US$755.61 million versus US$498.83 million a year earlier, and full-year 2025 sales of US$2.49 billion and net income of US$290.15 million. Alongside these results, management issued 2026 guidance calling for US$3.05–3.20 billion in revenue and US$11.65–12.25 in diluted EPS, signaling confidence in converting a much larger backlog and recent acquisitions into earnings. We will...

Soleno Therapeutics recently reported that its fourth-quarter 2025 results marked a shift to profitability, with net income of US$43.36 million and full-year net income of US$20.89 million, driven by the commercial launch of VYKAT XR for hyperphagia in Prader-Willi syndrome. The company also announced that long-time finance leader James Mackaness will retire and be succeeded by experienced biopharma and healthcare executive Jennifer Fulk as Chief Financial Officer, reinforcing its move from...

In February 2026, Borr Drilling reported fourth-quarter 2025 revenue of US$259.4 million and a net loss of US$1.0 million, alongside new and extended jack-up rig contracts across Mexico, Brunei, the U.S., Gabon, Congo, and offshore Germany that enhance fleet utilization and revenue visibility. An interesting angle is how this mix of lower quarterly profitability but fuller rig calendars could reshape views on Borr Drilling’s risk profile and earnings quality. Next, we’ll examine how these...

Why Black Stone Minerals Is In Focus After Its Latest Earnings Release Black Stone Minerals (BSM) is back on investors’ radar after releasing fourth quarter and full year 2025 results that highlighted higher revenue and net income, alongside fresh 2026 production guidance and detailed 2025 operating metrics. See our latest analysis for Black Stone Minerals. The earnings release and 2026 production guidance arrived after a steady run, with Black Stone Minerals’ share price showing an 11.77%...

Why the latest MRT-2359 data matters for Monte Rosa Therapeutics (GLUE) Monte Rosa Therapeutics (GLUE) is back on investors’ radar after updated clinical data for its MRT-2359 prostate cancer program, presented at the ASCO GU Symposium, supported a move into Phase 2 and potential registrational studies. See our latest analysis for Monte Rosa Therapeutics. Despite the positive MRT-2359 update and upcoming conference appearance, Monte Rosa Therapeutics’ recent momentum has cooled. The company...

TG Therapeutics recently reported fourth-quarter 2025 results showing revenue of US$192.57 million, up sharply from US$108.19 million a year earlier, while quarterly net income was essentially flat and earnings per share came in below analyst expectations. For 2025 as a whole, the company recorded US$616.29 million in revenue and a very large increase in net income to US$447.18 million, largely reflecting the growing contribution of BRIUMVI alongside raised guidance for 2026. We’ll now...

In February 2026, Ardent Health announced a partnership with hellocare.ai to roll out an enterprise AI platform for virtual nursing, telehealth, and patient safety monitoring across more than 2,000 inpatient rooms, aiming to enhance clinical capacity and standardize virtual care workflows. This move deepens Ardent’s digital transformation by combining AI-powered monitoring, purpose-built hardware, and clinical integration to create a unified, data-driven virtual care infrastructure that...

Earnings beat puts DiamondRock Hospitality (DRH) in focus Fresh off fourth quarter and full year 2025 results that topped Wall Street expectations on funds from operations, DiamondRock Hospitality (DRH) is back on investors’ radar as management outlines its next phase. See our latest analysis for DiamondRock Hospitality. At a share price of US$10.04, DiamondRock Hospitality has seen a 9.37% 1 month share price return and an 11.80% 3 month share price return, while its 1 year total shareholder...

American Healthcare REIT (AHR) has come into focus after launching and completing a sizeable at the market equity program, raising hundreds of millions of dollars alongside fresh earnings and 2026 guidance. See our latest analysis for American Healthcare REIT. The new equity program and recent capital raise come after a period of strong interest in American Healthcare REIT. The 30 day share price return is 11.36% and the year to date share price return is 10.58%, while the 1 year total...